Compass Therapeutics Reports Positive Phase 2/3 BTC Results
The company reported that tovecimig plus paclitaxel improved ORR to 18.0% versus 5.3% and median PFS to 4.7 versus 2.6 months in previously treated advanced biliary tract cancer (HR=0.44).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.